An assessment of transcriptional changes in porcine skin exposed to bromine vapor

2011 ◽  
Vol 25 (4) ◽  
pp. 252-262 ◽  
Author(s):  
James V. Rogers ◽  
Jennifer A. Price ◽  
Morgan Q. S. Wendling ◽  
Mark R. Perry ◽  
Frances M. Reid ◽  
...  
2009 ◽  
Vol 28 (3) ◽  
pp. 129-140 ◽  
Author(s):  
Jennifer A. Price ◽  
James V. Rogers ◽  
James N. McDougal ◽  
Morgan Q. Shaw ◽  
Frances M. Reid ◽  
...  

2011 ◽  
Vol 30 (3) ◽  
pp. 187-197 ◽  
Author(s):  
Jennifer A. Price ◽  
James V. Rogers ◽  
Morgan Q. S. Wendling ◽  
Jennifer L Plahovinsak ◽  
Mark R. Perry ◽  
...  

2013 ◽  
Vol 32 (11) ◽  
pp. 1207-1211
Author(s):  
Wu-quan LI ◽  
Xiao-chen QIU ◽  
Jun LIU ◽  
Di-nan WEI ◽  
Zong-hua CHEN ◽  
...  

2019 ◽  
Author(s):  
Simona Seizova ◽  
Alexandra L Garnham ◽  
Michael J Coffey ◽  
Lachlan W Whitehead ◽  
Kelly L Rogers ◽  
...  

2020 ◽  
Vol 26 (11) ◽  
pp. 1191-1205 ◽  
Author(s):  
Ranjit K. Harwansh ◽  
Shiv Bahadur ◽  
Rohitas Deshmukh ◽  
Md. A. Rahman

: Breast cancer (BC) is a multifactorial disease and becoming a major health issue in women throughout the globe. BC is a malignant type of cancer which results from transcriptional changes in proteins and genes. Besides the availability of modern medicines and detection tools, BC has become a topmost deadly disease and its cure still remains challenging. Nanotechnology based approaches are being employed for the diagnosis and treatment of BC at clinical stages. Nanosystems have a significant role in the study of the interaction of malignant cells with their microenvironment through receptor-based targeted approach. Nowadays, lipid-based nanocarriers are being popularized in the domain of pharmaceutical and medical biology for cancer therapy. Lipidic nanoparticlized systems (LNPs) have proven to have high loading efficiency, less toxicity, improved therapeutic efficacy, enhanced bioavailability and stability of the bioactive compounds compared to traditional drug delivery systems. In the present context, several LNPs based formulations have been undertaken in various phases of clinical trials in different countries. This review highlights the importance of chemotherapeutics based lipidic nanocarriers and their anticipated use for the treatment of BC. Furthermore, the clinical trials and future prospective of LNPs have been widely elaborated.


2020 ◽  
Vol 17 (2) ◽  
pp. 140-147
Author(s):  
Karna B. Ghimirey ◽  
Kevin Ita

Objective: In vitro diffusion experiments were performed to assess the permeation of magnesium sulfate across pig skin. Method: The mean thickness of the dermatomed porcine skin was 648 ± 12 µm. Magnesium concentration was measured using inductively coupled plasma-optical emission spectroscopy. Transdermal flux of magnesium sulfate across MN-treated and untreated porcine skin was obtained from the slope of the steady-state linear portion of cumulative amount versus time curve. Results: Statistical analysis of the results was done with Student’s t-test. The transdermal flux of magnesium sulfate across microneedle-treated porcine skin was 134.19 ± 2.4 µg/cm2/h and transdermal flux across untreated porcine skin was 4.64 ± 0.05 µg/cm2/h. Confocal microscopy was used to visualize the microchannels created by a solid microneedle roller (500 µm). Conclusion: From our confocal microscopy studies, it was evident that the 500 μm long microneedles disrupted the stratum corneum and created microchannels measuring 191 ± 37 µm. The increase in transdermal flux across the microneedle-treated skin was statistically significant compared to that of controls, i.e., without the application of microneedles. With the application of microneedles, the transdermal flux of magnesium permeated over 12 h was approximately 33-fold higher in comparison to passive diffusion across an intact stratum corneum.


BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Eddie Luidy Imada ◽  
Diego Fernando Sanchez ◽  
Wikum Dinalankara ◽  
Thiago Vidotto ◽  
Ericka M. Ebot ◽  
...  

Abstract Background PTEN is the most frequently lost tumor suppressor in primary prostate cancer (PCa) and its loss is associated with aggressive disease. However, the transcriptional changes associated with PTEN loss in PCa have not been described in detail. In this study, we highlight the transcriptional changes associated with PTEN loss in PCa. Methods Using a meta-analysis approach, we leveraged two large PCa cohorts with experimentally validated PTEN and ERG status by Immunohistochemistry (IHC), to derive a transcriptomic signature of PTEN loss, while also accounting for potential confounders due to ERG rearrangements. This signature was expanded to lncRNAs using the TCGA quantifications from the FC-R2 expression atlas. Results The signatures indicate a strong activation of both innate and adaptive immune systems upon PTEN loss, as well as an expected activation of cell-cycle genes. Moreover, we made use of our recently developed FC-R2 expression atlas to expand this signature to include many non-coding RNAs recently annotated by the FANTOM consortium. Highlighting potential novel lncRNAs associated with PTEN loss and PCa progression. Conclusion We created a PCa specific signature of the transcriptional landscape of PTEN loss that comprises both the coding and an extensive non-coding counterpart, highlighting potential new players in PCa progression. We also show that contrary to what is observed in other cancers, PTEN loss in PCa leads to increased activation of the immune system. These findings can help the development of new biomarkers and help guide therapy choices.


Sign in / Sign up

Export Citation Format

Share Document